Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "LLY's"


25 mentions found


Eli Lilly dips: Shares of Eli Lilly are sitting out the rally on news that Swiss pharmaceutical firm Roche 's experimental obesity drug demonstrated promise in a Phase 1 study. "Doug McMillon, the CEO of Walmart, made the point repeatedly that the company's success this quarter came from lower prices," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Eli Lilly, Roche, It's, inflect, We're, Doug McMillon, Estee Lauder, Jim, Jim Cramer's Organizations: CNBC, Viking Therapeutics, Club, Deere, Walgreens Boots, Walmart, Costco, Materials, Jim Cramer's Charitable Locations: Swiss, Amgen, China
Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company's bid to compete in the booming market for those treatments. But its weekly weight loss injection, called CT-388, is still years away from entering the market. The treatment works by mimicking the effect of two gut hormones — GLP-1 and GIP — to suppress a person's appetite, just like Eli Lilly's popular weight loss drug Zepbound and diabetes injection Mounjaro. Scientists have hypothesized that targeting those two hormones could have a meaningful effect on weight loss and blood sugar levels with fewer side effects than drugs that only target GLP-1, such as Novo Nordisk's weight loss treatment Wegovy. Eli Lilly's Zepbound delivered up to 22% weight loss after 72 weeks, while Novo Nordisk's Wegovy has led to 15% weight loss after 68 weeks.
Persons: Roche, Eli Lilly, Roche's, , Eli Lilly's, Eli Lilly's Zepbound, Novo Nordisk's Wegovy Organizations: Roche, AG, Carmot Therapeutics, Novo Nordisk, Novo Nordisk's Locations: Basel, Switzerland, Swiss, Roche's, Novo
AdvertisementThe unprecedented criminal trial of a former US president has delivered several stunning moments so far. Jurors get a peek at the 34 records at the heart of the caseTwo weeks into Trump's trial, jurors finally saw the paperwork at the heart of the matter. A courtroom sketch of Stormy Daniels on the witness stand in Donald Trump's hush-money trial. On the stand, Daniels said Trump told her she reminded him of his daughter, commenting on her blond hair and beauty. Trump's legal team requested a mistrial on the basis of Daniel's testimony.
Persons: , Donald Trump, Trump, Stormy Daniels, Michael Cohen —, Hope Hicks, Cohen, Daniels, Hicks, Andrew Harnik, Jeffrey McConney, Deborah Tarassoff —, Alvin Bragg, Stephanie Clifford, Donald Trump's, Jane Rosenberg, Juan Merchan, audibly, Merchan, Judge Merchan, MARK PETERSON, Donald, Von ShitzInPantz, Todd Blanche, Joe Biden, Blanche, Cohen's Organizations: Service, Business, White House, Trump, White House Communications, AP, Trump Organization, Prosecutors, Reuters, Truth, Manhattan Criminal, Getty Locations: Manhattan, Lake Tahoe, New York City
The three companies collectively operate 75 U.S. casinos that permit indoor smoking, where state law allows. States like Nevada and New Jersey have prohibited indoor smoking more broadly, but carved out exceptions for casinos. Legislation to end indoor smoking at casinos is in various stages in several states across the country, including New Jersey, Pennsylvania and Rhode Island. Advocates for smoking bans point to research by C3 Gaming that concluded smoke-free casinos generate more revenue and outperform competitors that allow smoking. In Las Vegas, MGM Resorts opened the first casino resort on the Strip to prohibit indoor smoking and even smoking on the pool deck.
Persons: Boyd, Bally's, it's, Jan Jones Blackhurst, we've, Marc Oppenheimer, we're, it'll Organizations: Boyd Gaming, Bally's Entertainment, Caesars Entertainment, Trinity Health, Nonsmokers, Rights Foundation, Trinity, Caesars, The Securities, Exchange Commission, C3 Gaming, SBC, North, United Auto Workers, Disease Control, U.S, CNBC, Las Vegas, MGM Resorts, MGM Locations: Livonia , Michigan, Bally's, U.S, Nevada, New Jersey, New Jersey , Pennsylvania, Rhode Island, North America, United States, Pennsylvania, Bensalem, Philadelphia, Las
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEarnings are the biggest driver of stocks, says Citi's Kristen BitterlyKristen Bitterly, head of investment solutions at Citi Global Wealth, joins 'Closing Bell' to discuss the market rally's staying power, earnings power, and more.
Persons: Citi's Kristen, Kristen Organizations: Citi Global Wealth
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC’s full interview with Citi's Kristen Bitterly, Virtus’ Joe Terranova and Merrill’s Chris HyzyCiti's Kristen Bitterly, Virtus' Joe Terranova, and Merrill's Chris Hyzy join 'Closing Bell' to discuss the market rally's staying power, earnings power, and more.
Persons: Citi's Kristen, Virtus ’ Joe Terranova, Merrill’s Chris Hyzy Citi's Kristen, Virtus, Joe Terranova, Chris Hyzy Organizations: Virtus ’
download the appSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read preview"One Tree Hill" star Chad Michael Murray's perspective on his acting career lately has been influenced by fatherhood. Murray and his wife Sarah Roemer, who co-starred on the TV show "Chosen," have three children together. The pair haven't publicly disclosed any of their names, but occasionally share photos of their kids on social media. "I don't want my kids going to school, being freshman in high school, and dad's butt posted all over their locker," Murray explained.
Persons: , Chad Michael Murray's, Murray, Sarah Roemer, he's, Roemer, Jim Kelly's, Sarah, I've, We've, emoji, Numéro Organizations: Service, Numéro, Business, Us Weekly, Buffalo Bills, Entertainment, Netflix
Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield
Read previewAn old video of Drake dancing with and kissing a 17-year-old has resurfaced again amid the rapper's feud with Kendrick Lamar. In the former, released Friday, Lamar suggests Drake is a "predator" and says he's got "sex offenders" at his record label, OVO. AdvertisementIn "Not Like Us," released less than a day later, Lamar outright calls Drake and his entourage pedophiles: "Certified Lover Boy? In 2019, many who took issue with the video of Drake compared his encounter with the 17-year-old to Kelly's behavior. Drake and Harris knew each other for several years before rumors that the two were dating circulated in 2018, when Harris was 18 and Drake was 31.
Persons: , Drake, Kendrick Lamar, Kendrick Lamar's, Lamar, he's, it's, Jeffrey Epstein, Millie Bobby Brown, Millie Bobby Browns, I'd, he'd, Lamar didn't, Prince Williams, Swan, Kelly, Aaliyah, Brown, Bella Harris, Harris Organizations: Service, Ogden, Guardian, Business, Drake, Getty, Hollywood, Washington DC Locations: Drake's Denver , Colorado, Washington
I went to a new Checkers near me shortly after it opened to try the chain for the first time. AdvertisementFast food isn't my first meal choice, but it comes in handy when I'm on the go. When a Checkers opened near me recently, I knew I had to try it out. Fast food is getting more expensive nowadays, so I'm always looking for the best value. I was excited to see if Checkers was worth including in my rotation.
Persons: , I'd Organizations: Service, Checkers
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "This is the kind of number you need that basically says the Fed is doing their job," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Coterra, naysayers, Eli Lilly, drugmaker Amgen, we're, Jim Cramer's, Jim Organizations: CNBC, Club, Apple, Coterra Energy, Mizuho Securities
The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.
Persons: , Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America
That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.
Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S
Footwear company Crocs has strong momentum, making it a solid play for investors ahead of earnings out next week, according to Bank of America. Analyst Christopher Nardone reiterated his buy rating and $150 price target, saying the stock is a winner in a "price-sensitive consumer environment." Nardone expects Crocs' international business, which accounts for 40% of its total sales, to be "the driver of outsized growth" for the quarter and full year. He forecasted total Crocs sales growth of 8% in the first quarter and 6% in the full year. "Nearer term, we think the market will be most focused on signs of improvement in both DTC and margins," for Heydude, Nardone said.
Persons: Crocs, Christopher Nardone, It's, Nardone, Terence Reilly's, Stanley, Steve Madden Organizations: Bank of America Locations: Asia, China, India
Bausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses — putting embattled shares under pressure. BHC YTD mountain Bausch Health YTD Bottom line Along with quarterly results, Bausch Health reaffirmed forward guidance. While not necessarily expected to see a massive increase in adoption in the future like Lilly's GLP-1s, Xifaxan currently accounts for 41% of Bausch Health sales, excluding B+L. Breaking that down: $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Bausch, Eli Lilly, It's, Xifaxan, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health, Bausch Health, Norwich Pharmaceuticals, Amneal Pharmaceuticals, Food and Drug Administration, Management, CNBC Locations: generics, Norwich
Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing mid-stage trial in obese or overweight adults without diabetes. The drugmaker's oral drug, called AMG-786, is the second weight loss pill to be discontinued over the last year. Investors are laser-focused on Amgen's pipeline of experimental weight loss treatments. Amgen's injectable treatment also appears to help patients keep weight off after they stop taking it based on some clinical trial data.
Persons: Amgen, Eli Lilly, Jay Bradner, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound Organizations: Novo Nordisk, Pfizer, Novo Nordisk's Locations: Amgen, Thousand Oaks , California, MariTide, Novo
The past few years have been tough for edtech companies. In recent months, multiple edtech startups have raised fresh funding rounds while specifically touting AI as a core part of their business model. These deals could signal that AI is ushering in a new era for edtech companies, and VCs who invest in the space are excited about the renaissance. And Ednition, also one of Donnelly's portfolio companies, provides an infrastructure-as-a-service platform for other edtech companies to improve the data that goes into their AI models. That's why it's so important to invest in ed-tech AI startups that help people rethink how they interact with technology and learn new skills necessary to successfully enter the workforce, he said.
Persons: PitchBook, VCs, Brian Dixon, Dixon, we've, Numerade, Kapoor, Katelyn Donnelly, she's, I've, you'll, Donnelly, Avalance, OpenAI, we're, ChatGPT, Ryan Craig, Craig, edtech Organizations: Business, Labs, Kapor, Partners, Chingona Ventures, TechCrunch, Kapoor Capital, Lirvana Labs, Odyssey Education, University Ventures, ACT Locations: VCs, edtech
Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S
The world's biggest healthcare company said it experienced surging demand for its GLP-1 Zepbound weight loss drug. Eli Lilly raised its 2024 revenue guidance, suggesting that the supply shortage of its weight loss drug may soon ease. The results showed soaring demand for its GLP-1 weight loss drug Zepbound, and the revenue guidance increase suggests that ongoing supply shortages of the drug may soon ease. "We have approximately 67% access in the commercial segment," Eli Lilly CFO Anat Ashkenazi said on the company's earnings call. Eli Lilly is looking to expand its indications of Zepbound so it can treat more health problems, including sleep apnea.
Persons: Eli Lilly, , Zepbound, David Ricks, Eli Lilly's, Anat Ashkenazi, Ashkenazi, LLY, JPMorgan, JPMorgan isn't Organizations: Service, JPMorgan Locations: America
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald managing director, joins 'Squawk Box' to discuss Eli Lilly's quarterly earnings results, weight loss drug demand, growth outlook, and more.
Persons: Eli Lilly, Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald, Eli
"One of the things we know about the brain and memory is that 'use it or lose it' absolutely applies," she tells CNBC Make It. "If you tend to always rely on Google to remember a particular fact, for example, and don't 'use' your brain to remember it, your brain gets very good at not remembering it." If you tend to always rely on Google to remember a particular fact ... your brain gets very good at not remembering it. Here are three simple steps you can take to wean yourself of Google and improve your recall. "Even if this doesn't work at first, and you end up having to Google it anyway, you will slowly strengthen your memory pathways and improve your recall," she says.
Persons: I've, Cynthia Borja, Borja, It's, Bill Gates Organizations: CNBC, Google
The Copenhagen-based firm subadvises funds like the Harbor International Compounders ETF (OSEA), which O'Reilly has co-managed since its launch in early September 2022. But despite launching less than two years ago, O'Reilly said in a recent interview that the ETF's success didn't happen overnight. "We feel the strategy that we have can work in any market environment," O'Reilly said. The ETF is more balanced when it comes to countries, as no more than 13% of its stocks are from a single nation. 5 international stocks to buy nowAfter outlining his investing strategy, O'Reilly spoke about five companies he's especially excited about now.
Persons: Peter O'Reilly, who's, O'Reilly, You've, he's, Germany — Organizations: London, Asset Management, Business, Carnegie Asset Management Locations: Ireland, Dublin, Copenhagen, France, Japan, United Kingdom, Germany
Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.
Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S
Analyst Edward Kelly upgraded the discount retailer to overweight from equal weight and opened a $180 price target. Yefremov's $400 price target indicates shares can jump 31.7% from Wednesday's closing price. Analyst Andrea Teixeira downgraded the energy drink maker to neutral from overweight and cut her price target by $7 to $59. — Alex Harring 5:38 a.m.: Wall Street reacts to Meta earnings Meta Platforms disappointed investors with its weak revenue guidance , sending shares down about 13% in premarket trading. His price target of $55 implies upside of 22% over the next 12 months.
Persons: Bernstein, Wells, Edward Kelly, shrinkflation, Kelly, — Alex Harring, Sherwin, Williams, Aleksey Yefremov, Yefremov, Doug Creutz, Creutz, Judas, Goldman, bullish, Goldman Sachs, Brooke Roach, Roach, Andrea Teixeira, Alex Harring, Ford, Wells Fargo, Colin Langan, Langan, LSEG, Eric Sheridan, Brian Nowak, Morgan Stanley, Doug Anmuth, Ronald Josey, Daniel Roeska, Roeska, General Motors, Fred Imbert Organizations: CNBC, General Motors, Traders, Grand Theft, Sony, Electronic Arts, TJX, TJX Companies, JPMorgan, Monster Beverage, Ford, Ford Pro, Facebook, Meta, Citi, mojo, General, GM Locations: Wells Fargo, Thursday's, Wednesday's, Michigan
Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Broadcom : Broadcom's AI business, which includes co-designing custom chips for tech giants such as Club holding Alphabet, is booming. The newspaper reported April 12 that Salesforce was in talks to buy Informatica, which sent the Club holding's shares plunging. Wells Fargo : Another trim is due for our Wells Fargo position after a great run for the bank stock, Jim argued. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Jim Cramer's, Jim, Johnson, Abbott, Andy Jassy, Bausch, Salesforce, Salesforce didn't, Tom Jorden, We've, It's, Walt Disney, Nelson Peltz's, Bob Iger's, Estee Lauder, there's, Eaton, We're, he's, Locker, he'd, Vimal Kapur, Linde, Eli Lilly, Eli Lilly's, TikTok, Joe Biden, Morgan Stanley, Morgan Stanley's, Ted Pick, Jensen Huang, Nikesh Arora, haven't, Laxman Narasimhan, Sands, Stanley Black, Decker, TJ Maxx, TJX, Wells, Jim Cramer, Angela Weiss Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Johnson, Web Services, Broadcom, VMWare, GE Healthcare, GE, Bausch Health, Costco Wholesale, Costco, Street, Informatica, Coterra, DuPont De Nemours, DuPont, Walt, Disney, Ford, GM, Philips, Siemens, Google, Honeywell, Linde, Facebook, Meta, Microsoft, Nvidia, Investors, AMD, Oregon State University, Palo Alto Networks, UnitedHealth, Procter & Gamble, Constellation Brands, Constellation, Modelo, TJX, Marshalls, Home Goods, Wynn Resorts, Jim Cramer's Charitable, New York Stock Exchange, Afp, Getty Locations: China, Informatica, Ford, Estee, U.S, mater, Palo, Corona, Wells Fargo, Wells, Macao, New York City
Total: 25